2026
conference-abstract
OpenAlex
Esther Redín, Bárbara Piffero Mello, Yingian A. Zhan, Nicholas Socci et autres
Abstract ALK gene fusions drive oncogenesis in ∼5% of lung adenocarcinomas (LUADs), and ALK tyrosine kinase inhibitors (TKIs) such as lorlatinib have improved outcomes. However, acquired resistance remains a challenge, with >30% of mechanisms unknown. To uncover novel drivers of resistance, we …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Jierui Xu, Henry S. Walch, Maria Perry, Christopher J. Fong et autres
Abstract Introduction: Whole-genome duplication (WGD) is a pervasive event in cancer evolution, conferring tolerance to large-scale genomic alterations and reshaping selective pressures. While WGD is linked to aneuploidy and poor prognosis, its impact on metastatic risk across cancer types remains unclear. We …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Alexander Lim, Wei Tian, Zhuoning Li, Mara Monetti et autres
Abstract Background: Uveal melanoma (UM) is a rare but aggressive melanoma subtype with limited response to immune checkpoint inhibitors. Identifying tumor-specific or associated antigens and tumor-reactive T cells is critical to advancing precision immunotherapy. Patient-derived tumor organoids (PDOs) offer a physiologically relevant …
us
(code pays fourni par la source)